Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Evotec : invests in Exscientia to advance AI-driven drug discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:17am CEST

Release date- 29092017 - Hamburg, Germany, Dundee, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd ('Exscientia') today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.

Through this investment, Evotec becomes the first strategic shareholder in the UK-based company. Exscientia is focused on Artificial Intelligence ('AI')-driven drug discovery and design. With more than 1,800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.

Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. The ongoing success of this partnership was the basis of this expanded and deepened corporate relationship. Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner. Exscientia's approach fuses the power of AI with the discovery experience of seasoned drug hunters and chemistry experts. This investment will enable Exscientia to drive higher value partner programmes and expand discovery on its automated design platform.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: 'Our investment in Exscientia represents Evotec's single biggest equity placement to date and in, what we feel, is the world leading AI technology company. Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery. We are very excited about the joint potential to leverage AI in chemistry. This investment is also the first time that we can efficiently use our recently awarded EUR 75 m loan facility from the European Investment Bank to bring down cost of capital for such an investment.'

Commenting on the investment, Prof. Andrew Hopkins, Chief Executive Officer of Exscientia, added: 'Exscientia and Evotec have built a close relationship over the past year sharing mutual interest in agile innovation. We are delighted that Evotec has made this investment for a minority equity stake, allowing Exscientia to deliver more drug discovery projects in a rapid and capital efficient manner. I'm also delighted that Dr Mario Polywka, Chief Operating Officer of Evotec, will join Exscientia's Board of Directors, allowing us to benefit from his strong operational expertise in growing successful biotech companies.'

About Exscientia and AI-driven drug discovery

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

The innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by Exscientia's AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes.

By applying a rapid design-make-test cycle, the Exscientia AI system actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi (metabolic disease), Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals (CNS) and GSK. Exscientia was established as a spinout company from Prof. Andrew Hopkins laboratory at the University of Dundee.

Contact:

Mark Swallow

Tel: +44 207 638 9571

Email: [email protected]

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
04/19EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
AQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
04/18EVOTEC : and Bayer Advance Third Endometriosis Programme into Phase I Clinical D..
BU
04/18EVOTEC : And bayer advance third endometriosis programme into phase i clinical d..
EQ
04/16EVOTEC : forms collaboration with Petra Pharma on INDiGO platform
AQ
More news
News from SeekingAlpha
04/11Petra Pharma teams up with Evotec to develop lead candidate Petra-01 
03/28Evotec AG 2017 Q4 - Results - Earnings Call Slides 
03/28Evotec's (EVOTF) CEO Werner Lanthaler on Q4 2017 Results - Earnings Call Tran.. 
03/28Evotec AG reports FY results 
03/26Evotec launches accelerated drug development service 
Financials (€)
Sales 2018 324 M
EBIT 2018 57,9 M
Net income 2018 44,0 M
Debt 2018 69,7 M
Yield 2018 -
P/E ratio 2018 46,53
P/E ratio 2019 39,52
EV / Sales 2018 6,79x
EV / Sales 2019 5,87x
Capitalization 2 128 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,5 €
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG6.85%2 615
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873